Abstract
Objective
To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/hyperactivity disorder (ADHD).
Method
Four hundred and sixteen children and adolescents with ADHD whose symptoms remitted during initial 10-week, open-label atomoxetine treatment were randomly assigned to continue with atomoxetine or placebo.
Results
In all, 43% met criteria for comorbid ODD. A total of 17% of patients with comorbid ODD relapsed (CGI-Severity score ≥ 3 and ADHD Rating Scale total score of 90% or more of baseline at study entry on two consecutive visits) during atomoxetine treatment, compared with 26% of patients without comorbid ODD (RR 0.67, 95% CI 0.42–1.06). Mean time to relapse was not significantly different [mean (SE) days to relapse, ADHD/ +ODD: 215 (7.38); ADHD/–ODD: 211 (7.61); log rank p=0.08]. This finding is placed within the context of atomoxetine affording an overall protection against relapse compared with placebo (RR 0.59, 95% CI 0.43–0.80).
Conclusions
Comorbid ODD does not influence the rate of relapse of patients with ADHD during longer-term treatment with atomoxetine. Atomoxetine protects against the relapse of ADHD symptoms regardless of the presence or absence of comorbid ODD.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Angold A, Costello EJ, Erkanli A (1999) Comorbidity. J Child Psychol Psychiatry 40:57–87
Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A (2003) Association of ADHD and conduct disorder—brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44:356–376
Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2005) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(Suppl 1):i102–i116
Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ, Atomoxetine ADHD Study Group (2002) Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 110:e75
Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, Wilens TE, Frazier E, Johnson MA (2002) Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159:36–42
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. The Guilford Press, New York
Faraone SV, Biederman J, Monuteaux MC (2000) Attention-deficit disorder and conduct disorder in girls: evidence for a familial subtype. Biol Psychiatry 48:21–29
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, Revised. United States Department of Health, Education, and Welfare, Bethesda, Md
Hazell P (1997) The overlap of attention deficit hyperactivity disorder with other common mental disorders. J Pædiatr Child Health 33:131–137
Hazell PL, Stuart JE (2003) A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 42:886–894
Jensen PS (2001) Introduction–ADHD comorbidity and treatment outcomes in the MTA. J Am Acad Child Adolesc Psychiatry 40:134–136
Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B (2001) ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 40:147–158
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Kaufman J, Birmaher B, Brent D, Rao U, Ryan N (1996) Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). University of Pittsburgh Press, Pittsburgh
Lachin JM, Foulkes MA (1986) Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42:507–519
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901
Michelson D, Buitelaar J, Danckaerts MJ, Gillberg C, Spencer T, Zuddas A, Faries D, Zhang S (2004) Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:896–904
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
MTA Cooperative Group (1999) Development of clinical services for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1097–1099
MTA Cooperative Group (1999) Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1088–1096
Newcorn J, Michelson D, Spencer T, Milton D (2002) Atomoxetine treatment in child/adolescent ADHD with comorbid ODD. Presented at: The 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 22–27:2002; San Francisco, Calif
Pliszka SR (1989) Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 28:882–887
Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV,Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693–695
Spencer TJ, Biederman J, Wilens TE, Faraone SV (2002) Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 63 (Suppl 12):16–22
Walkup JT, Labellarte MJ, Riddle MA, Pine D, Greenhill L, Klein R, Davies M, Sweeney M, Fu C, Abikoff H, Hack S, Klee B, McCracken J, Bergman L, Piacentini J, March J, Compton S, Robinson J, O’Hara T, Baker S, Vitiello B, Ritz L, Roper M (2003) Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:13–21
World Medical Association (2000) Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. As adopted by the 18th General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd General Assembly, Edinburgh, Scotland, October 2000
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hazell, P., Zhang, S., Wolańczyk, T. et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 15, 105–110 (2006). https://doi.org/10.1007/s00787-006-0506-y
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00787-006-0506-y